Platelet Production in a Pulmonary-based Microfluidic Reactor
基于肺的微流体反应器中的血小板生产
基本信息
- 批准号:9907840
- 负责人:
- 金额:$ 30.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlternative TherapiesBedsBindingBiologicalBiologyBiomedical EngineeringBloodBlood Platelet DisordersBlood PlateletsBlood flowBone MarrowCaringCharacteristicsClinicClinicalCollaborationsDataDevelopmentDevicesDimensionsEndotheliumEnvironmentFutureGasesGenerationsGeometryHumanImmobilizationIn VitroInfusion proceduresLaboratoriesLeadLungMalignant NeoplasmsMeasurementMeasuresMechanical StimulationMechanicsMegakaryocytesMicrofluidic MicrochipsMicrofluidicsMicroscopicModelingModern MedicinePartial PressurePatientsPerformancePeriodicityPhasePhysiologicalPlatelet Count measurementPlatelet TransfusionProductionPropertyPulmonary Gas ExchangeReportingResearchResearch Project GrantsRestRiskSafetyStreamSurfaceSystemTestingThinnessThrombopoiesisTimeTransfusionVenousWorkbasecapillary beddemographicsdesigndisease transmissionflexibilityimprovedin vivoinstrumentmechanical drivemimeticsparticleplatelet functionpost-traumapressureresponsescale upsuccesssystems researchtoolvascular bed
项目摘要
ABSTRACT
Platelet transfusions are used to treat deficiencies in platelet number and/or function that is seen in multiple
clinical settings such as cancer and post trauma. Given changing demographics and an increasing reliance on
platelet transfusion in modern medicine, its is likely that donor-derived platelets to provide this care may prove
inadequate in the near future. The generation of large numbers of physiologically viable platelets in-vitro is
intended to provide a new treatment option for such patients with platelet deficies. Starting with mega-
karyocytes (Megs), platelet release (thrombopoiesis) is driven by shear forces typically found in the
vasculatures. Previous approaches were aimed at mimicking platelet production in the bone marrow as Megs
emerge from the intramedullary space into the blood stream, but new research points to significant platelet
production by Megs embedded in the lung. This proposal is aimed at taking advantage of this discovery to
improve both our understanding of thrombopoiesis and our ability to produce platelets in vitro focused on
mimicking the particular properties of the pulmonary microvasculature.
There are four aims in this application: Aim 1: Produce and test devices recapitulating the pulmonary
vascular bed. Several different will be manufactured to entrap Megs and allow thrombopoiesis to occur. Aim
2: Design and test a system for platelet production under lung-mimetic mechanical strain. We will use
flexible microfluidic layers will b. Aim 3: Design and test a system for temporal control of O2 concentration
within the reactor. Switching from a low to high O2 partial will be achieved to replicated physiological changes
in the lung. Aim 4: Optimize the combined effects of lung model parameters and test platelet functional
performance. The final microfluidic devices using all of the optimal parameter determined will be tested by
infusions of Megs and measurement of the efficacy to produce platelet-like particles that physically and
functionally match that of freshly-drawn donor-derived platelets.
Phase I research is intended to validate a consumable compatible with existing controllers that can we used
widely to study platelet production lung microenvironment by controlling cappillary, shear forces, defomation of
capillary bed and gas concentration. If successful, a scale-up to a clinically feasible platelet production reactor
will be attepted in Phase II. This work represents a collaboration between a bioengineering company that has
been supplying microfluidic research systems for the study of platelet function and a laboratory that are domain
experts in the treatment of platelet disorders.
摘要
血小板输注用于治疗血小板数量和/或功能的缺陷,这在多种疾病中可见。
临床环境,如癌症和创伤后。鉴于人口结构的变化和对
血小板输注在现代医学中,其很可能是供者来源的血小板提供这种护理可能证明
在不久的将来,不足。在体外产生大量生理上可行的血小板是
旨在为这类血小板缺陷患者提供一种新的治疗选择。从巨型开始-
在有核细胞(Megs)中,血小板释放(血小板生成)由通常在有核细胞(Megs)中发现的剪切力驱动。
血管以前的方法旨在模拟骨髓中血小板的产生,
从髓腔进入血液,但新的研究指出,
植入肺部的细胞该提案旨在利用这一发现,
提高我们对血小板生成的理解和体外产生血小板的能力,
模仿肺微血管的特殊性质。
本申请有四个目的:目的1:生产和测试重现肺动脉的器械
血管床将生产几种不同的产品来捕获Megs并允许发生血小板生成。目的
2:设计并测试在肺模拟机械应变下生产血小板的系统。我们将使用
柔性微流体层将B。目标3:设计和测试用于O2浓度的时间控制的系统
在反应堆内。将实现从低到高O2部分的切换,以复制生理变化
在肺部。目的4:优化肺模型参数的组合效应,检测血小板功能
性能使用所确定的所有最佳参数的最终微流体装置将通过以下测试:
输注Megs和测量产生血小板样颗粒的功效,
功能上与新鲜抽取的供体来源的血小板相匹配。
第一阶段研究的目的是验证与现有控制器兼容的耗材,
广泛研究血小板生产肺微环境,通过控制毛细血管,剪切力,变形,
毛细管床和气体浓度。如果成功的话,将扩大到临床上可行的血小板生产反应器
将在第二阶段进行验证。这项工作代表了一家生物工程公司之间的合作,
一直提供微流体研究系统的血小板功能的研究和实验室,是域
治疗血小板疾病的专家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALI YEHIA其他文献
ALI YEHIA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 30.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 30.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 30.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)